These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38558458)

  • 1. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
    Kim J; Park S; Kim S; Ryu S; Hwang H; Cho S; Han Y; Kim J; Park Y; Lee EK; Lee M
    Prostate; 2024 Jun; 84(9):814-822. PubMed ID: 38558458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.
    Sanità P; Capulli M; Teti A; Galatioto GP; Vicentini C; Chiarugi P; Bologna M; Angelucci A
    BMC Cancer; 2014 Mar; 14():154. PubMed ID: 24597899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
    Peak TC; Panigrahi GK; Praharaj PP; Su Y; Shi L; Chyr J; Rivera-Chávez J; Flores-Bocanegra L; Singh R; Vander Griend DJ; Oberlies NH; Kerr BA; Hemal A; Bitting RL; Deep G
    Mol Carcinog; 2020 Jan; 59(1):62-72. PubMed ID: 31674708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
    Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
    Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
    Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.
    Sommer U; Siciliano T; Ebersbach C; Beier AK; Stope MB; Jöhrens K; Baretton GB; Borkowetz A; Thomas C; Erb HHH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.
    Nouruzi S; Johnson F; Kumar S; Sivak O; Tabrizian N; Koistinaho M; Muona A; Zoubeidi A
    Oncol Rep; 2024 Oct; 52(4):. PubMed ID: 39129317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
    Verma S; Shankar E; Chan ER; Gupta S
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition.
    Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT
    Oncogene; 2020 Apr; 39(17):3555-3570. PubMed ID: 32123312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
    Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.